Eugenio De Corso on Dupixent for treating CRSwNP and asthma
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
By Brian Buntz | June 25, 2025| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
By Brian Buntz | April 30, 2025| Drug Discovery and Development
